Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 503

recruiting
3 972
countries
28
conditions
2 123

10 535 trials match your criteria

Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:Alogabat

Obesity+1

Not recruiting

A Phase 3 Study of Once‑Monthly PF‑08653944 vs Placebo for Weight Loss in Adults with Overweight or Obesity

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Berobenatide

Breast cancer

Not recruiting

Study of Camizestrant plus Ribociclib as First‑Line Treatment for Patients with ER‑Positive, HER2‑Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant

HIV infection

Not recruiting

Cabotegravir and Rilpivirine Ultra‑Long‑Acting vs Long‑Acting in Adults and Adolescents with HIV Who Are Virally Suppressed

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabotegravir

Hereditary ataxia

Not recruiting

Safety and tolerability of intrathecal S233107 in participants with spinocerebellar ataxia type 3: a Phase 1b/2a first‑in‑human randomized study

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:S233107

Obesity

Not recruiting

Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide

Obesity+1

Not recruiting

Study comparing two forms of cagrilintide with placebo for weight loss in adults with overweight or obesity

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide

Cardiac amyloidosis

Not recruiting

Efficacy and safety of eplontersen sodium plus ALXN2220 in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220

Narcolepsy

Not recruiting

Efficacy and Safety of E2086 in Adults with Narcolepsy: A Randomized, Double‑Blind, Placebo‑Controlled Trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ledasorexton

Overweight

Not recruiting

Study of PF-08653945 Bioavailability After Subcutaneous Injection in the Thigh, Upper Arm, or Abdomen in Adults with Obesity

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:PF-08653945

Multiple sclerosis

Not recruiting

Safety and Feasibility of Home Use On-Body Injection System for Subcutaneous Ocrelizumab in Adults with Multiple Sclerosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab

Ovarian cancer

Not recruiting

Open‑Label Extension Study of Avutometinib Alone or with Defactinib in Patients with Recurrent Low‑Grade Serous Ovarian Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avutometinib
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.